Health
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test – News-Medical.net
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity…
-
Noosa News23 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News24 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business17 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
General22 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands